December 28, 2004; 63 (12 suppl 6) Articles
Mitoxantrone treatment of multiple sclerosis
Safety considerations
Bruce A. Cohen, Daniel D. Mikol
First published December 28, 2004, DOI: https://doi.org/10.1212/WNL.63.12_suppl_6.S28
Mitoxantrone treatment of multiple sclerosis
Safety considerations
Bruce A. Cohen, Daniel D. Mikol
Neurology Dec 2004, 63 (12 suppl 6) S28-S32; DOI: 10.1212/WNL.63.12_suppl_6.S28
Citation Manager Formats
Make Comment
See Comments

Article Information
vol. 63 no. 12 suppl 6 S28-S32
PubMed:
Print ISSN:
Online ISSN:
History:
- First Published December 28, 2004.
Copyright & Usage:
© 2004
Author Disclosures
- Bruce A. Cohen, MD and
- Daniel D. Mikol, MD, PhD
- Bruce A. Cohen, MD and
- Daniel D. Mikol, MD, PhD
- From the Davee Department of Neurology, Northwestern University, Chicago, Illinois (Dr. Cohen) and the Department of Neurology, University of Michigan, Ann Arbor, Michigan (Dr. Mikol).
- Address correspondence and reprint requests to Dr. Bruce A. Cohen, Northwestern University Department of Neurology, 710 North Lake Shore Drive, Abbott Hall 1121, Chicago, IL 60611; e-mail: bac106{at}northwestern.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
- Reply to Pratt et al
- Bruce A. Cohen M.D., Davee Dept of Neurology, Feinberg School of Medicine, Northwestern University, 710 North Lake Shore Drive, Abbott Hall 1121, Chicago Illinois 60611bac106@northwestern.edu
- Daniel D. Mikol, M.D. Ph.D
Submitted June 07, 2005 - Mitoxantrone treatment of multiple sclerosis: Safety considerations
- Robert G. Pratt, PharmD, FDA, Center for Drug Evaluation and Research, 5600 Fishers Lane, HFD-430 Rockville, MD 20857prattr@cder.fda.gov
- Gerard A. Boehm, MD, MPH, Cindy M. Kortepeter, PharmD, Judith A. Racoosin, MD, MPH
Submitted June 07, 2005
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Advertisement
Related Articles
- No related articles found.